Shorter trastuzumab treatment for HER2+ breast cancer can be as effective, with fewer cardiac side-effects
A phase III randomized clinical trial of 4,088 women with HER2-positive, early-stage breast cancer found that taking trastuzumab (Herceptin) for 6 months was non-inferior to the current standard of 12 months. The disease-free ...
May 17, 2018
0
4